within Pharmacolibrary.Drugs.ATC.L;

model L01XX36
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.5333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 7 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.010199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0275,
    k12             = 3.74,
    k21             = 3.74
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX36</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oblimersen is an antisense oligonucleotide designed to target the messenger RNA of the BCL-2 protein, inducing apoptosis in tumor cells by reducing BCL-2 expression. Investigated in several cancers, especially chronic lymphocytic leukemia and melanoma, oblimersen has not gained regulatory approval and is not currently in widespread clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from literature, typical oncology intravenous dosing in adults; population: adult cancer patients.</p><h4>References</h4><ol><li><p>Galatin, PS, et al., &amp; Sikic, BI (2011). Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. <i>Investigational new drugs</i> 29(5) 971–977. DOI:<a href=\"https://doi.org/10.1007/s10637-010-9416-4\">10.1007/s10637-010-9416-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20349264/\">https://pubmed.ncbi.nlm.nih.gov/20349264</a></p></li><li><p>Margolin, K, et al., &amp; Gandara, DR (2007). Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of cancer research and clinical oncology</i> 133(10) 705–711. DOI:<a href=\"https://doi.org/10.1007/s00432-007-0200-6\">10.1007/s00432-007-0200-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17508219/\">https://pubmed.ncbi.nlm.nih.gov/17508219</a></p></li><li><p>O&#x27;Brien, SM, et al., &amp; Rai, KR (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 23(30) 7697–7702. DOI:<a href=\"https://doi.org/10.1200/JCO.2005.02.4364\">10.1200/JCO.2005.02.4364</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16186597/\">https://pubmed.ncbi.nlm.nih.gov/16186597</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX36;
